The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | HMA with or without venetoclax in treatment-naïve MDS with excess blasts: a retrospective analysis
Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses findings from a retrospective analysis comparing treatment with a hypomethylating agent (HMA) with and without venetoclax in treatment-naïve myelodysplastic syndromes (MDS) with excess blasts. Dr Bataller highlights a higher overall response rate (ORR) with HMA-venetoclax and discusses potential subgroups, including patients with ASXL1 mutations or higher blast counts, who may benefit most from the addition of venetoclax. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So in our analysis, what we did basically was to analyze a retrospective cohort of patients treated with either HMA or HMA and venetoclax. All of them were patients with MDS and excess blasts. Now, what we found is that patients with HMA-venetoclax had a superior overall response rate compared to HMA, although if we compare head-to-head, both the survival was kind of like similar around like 19 to 19 months of median overall survival...
So in our analysis, what we did basically was to analyze a retrospective cohort of patients treated with either HMA or HMA and venetoclax. All of them were patients with MDS and excess blasts. Now, what we found is that patients with HMA-venetoclax had a superior overall response rate compared to HMA, although if we compare head-to-head, both the survival was kind of like similar around like 19 to 19 months of median overall survival. Now, when we looked specifically at some subgroups, we could see that there are some subgroups, like for example, patients with ASXL1 mutation or patients with a blast percentage more than 10%, those patients seem to benefit most from the addition of venetoclax compared to HMA single agent. So this is what the key findings also show that transplant really impacts survival in both patients either treated with HMA and HMA-venetoclax. So basically, we need to find out which are these subgroups of patients that may benefit from venetoclax and also what is the role of transplant in combination with HMA-venetoclax in these patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
